Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

BACKGROUND: Adherence to chronic obstructive pulmonary disease (COPD) maintenance medication is important for managing symptoms and exacerbation risk, and is associated with reduced mortality, hospitalizations, and costs. This study compared on-treatment exacerbations, medical costs, and medication...

Descripción completa

Detalles Bibliográficos
Autores principales: Slade, David, Ray, Riju, Moretz, Chad, Germain, Guillaume, Laliberté, François, Shen, Qin, Duh, Mei Sheng, Mahendran, Malena, Hahn, Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325860/
https://www.ncbi.nlm.nih.gov/pubmed/34332555
http://dx.doi.org/10.1186/s12890-021-01612-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325860/
https://www.ncbi.nlm.nih.gov/pubmed/34332555
http://dx.doi.org/10.1186/s12890-021-01612-5

Ejemplares similares